IL4 and hemorrhagic cystitis: Administration of recombinant IL-4 alleviates IHC via attenuation of bladder TNF-α, IL-1β, iNOS, and cyclooxygenase 2 (COX-2) (10), which are proinflammatory mediators previously associated with hemorrhagic cystitis (2, 11, , , , –16).